Back to top

Halozyme price target raised to $105 from $93 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Halozyme (HALO) to $105 from $93 and keeps an Overweight rating on the shares....

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Halozyme Therapeutics, Inc. (HALO)